# FDA Schedules Advisory Committee Meeting to Review GRAIL Galleri Multi-Cancer Early Detection Test PMA

> fda · REPORTED · 2026-08-07

GRAIL announced on August 7, 2026 that the FDA has scheduled an advisory committee meeting to review the premarket approval application for the Galleri multi-cancer early detection blood test, a pivotal regulatory milestone for the first-of-its-kind liquid biopsy test that screens for more than 50 cancer types. This FDA advisory committee review is a critical step toward potential PMA approval for a test with major implications across oncology and women's health.

About GRAIL Inc.: GRAIL is a healthcare company focused on the early detection of cancer through its Galleri blood-based multi-cancer early detection test, which uses next-generation sequencing and machine learning to identify cancer signals across more than 50 cancer types from a single blood draw.

- Company: GRAIL Inc.
- Sector: diagnostics
- Primary source: https://www.medindia.net/health-press-release/curium-acquires-abscint-sa-expanding-pet-radiodiagnostic-pipeline-in-oncology-757554-1.htm

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.